NEW YORK, NY / ACCESSWIRE / July 7, 2022 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Axsome Therapeutics, Inc. (NASDAQ:AXSM)
CONTACT JAKUBOWITZ ABOUT AXSM:
https://claimyourloss.com/securities/axsome-therapeutics-inc-loss-submission-form/?id=29630&from=1
Class Period : December 30, 2019 – April 22, 2022
Lead Plaintiff Deadline : July 12, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Axsome’s chemistry, manufacturing, and control (“CMC”) practices were deficient with respect to AXS-07, the Company’s medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application (“NDA”) on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration (“FDA”) reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07’s regulatory and commercial prospects; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Spero Therapeutics, Inc. (NASDAQ:SPRO)
CONTACT JAKUBOWITZ ABOUT SPRO:
https://claimyourloss.com/securities/spero-therapeutics-inc-loss-submission-form/?id=29630&from=1
Class Period : October 28, 2021 – May 2, 2022
Lead Plaintiff Deadline : July 25, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the data submitted in support of the New Drug Application (“NDA”) for the Company’s product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration (“FDA”); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero’s operations; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Apyx Medical Corporation (NASDAQ:APYX)
CONTACT JAKUBOWITZ ABOUT APYX:
https://claimyourloss.com/securities/apyx-medical-corporation-loss-submission-form/?id=29630&from=1
Class Period : May 12, 2021 – March 11, 2022
Lead Plaintiff Deadline : August 5, 2022
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) a significant number of Apyx’s Advanced Energy products were used for off-label indications; (2) such off-label uses led to an increase in the number of medical device reports filed by Apyx reporting serious adverse events; (3) as a result, the Company was reasonably likely to incur regulatory scrutiny; (4) as a result of the foregoing, the Company’s financial results would be adversely impacted; and (5) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE : Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/707896/LAWSUITS-FILED-AGAINST-AXSM-SPRO-and-APYX–Jakubowitz-Law-Pursues-Shareholders-Claims
